Pharma is understandably risk-averse, and many companies remain in pilot mode, running small experiments that never scale.
To understand the complexities in more detail and the importance of targeting underserved populations, Digital Journal spoke with Mark Blumling, CEO and founder of Headlands Research, a recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback